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Abstract 
 
Background 
The National Institute of Health and Care Excellence makes use of registers to 
collect data for technologies that require more evidence to inform future decision-
making. This is particularly so for the Interventional Procedures Programme, which 
since 2003 has produced guidance for procedures that are typically not well 
established, meaning that named registers are often recommended for future data 
collection.  
 
Methods 
We constructed a questionnaire based on quality standards for recommended 
registers defined by the Interventional Procedures Programme. All guidance from 
2003 to 2016 were reviewed to identify recommended registers and compile a list of 
corresponding registries. We made a maximum of four attempts to contact each 
register. Each register was scored on seven quality standards: accessibility, 
responsiveness,  data publication, data coverage, data validity, independent 
oversight and data protection, with a maximum of 14 points. 
 
Results 
We obtained responses from 17 out of 24 eligible registries, a response rate of 
70.8%. The mean total score was 8.5 (standard deviation 2.9,  range 4 to 14). 
Overall, the quality of recommended registers was disappointing, with a split 
between large registries that scored highly across all standards and smaller 
registries that scored poorly. 
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Conclusion 
This the first study to our knowledge to assess the quality of registers recommended 
by health technology assessment agencies. Only a limited number of registers were 
mature enough to deliver evidence of sufficiently high quality to inform funding 
decisions. A standardised quality assessment tool is needed to evaluate registers 
before their recommendation for observational data gathering by decision-making 
bodies. 
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Introduction 
There is increasing pressure on health service funders around the world to 
accelerate the review process for new technologies in order to give patients early 
access to potentially transformative technologies (1,2). All proposals for early access 
require the support of ongoing safety and efficacy monitoring through observational 
data gathered after new technologies are available on the market. This can identify 
clinically important adverse effects that are less frequent in research than real world 
conditions, as well as assess the effectiveness of apparently efficacious technologies 
(3).  
 
Studies based on routinely collected health service data could be an efficient way of 
assessing effectiveness, but methodological challenges include appropriate 
identification of comparator data and insufficiency of data for case mix adjustment 
(4). There is therefore a place for well conducted observational data gathering 
through registers. Regulators have been concerned about the quality of evidence 
gathered in this way, however, leading to the development of quality standards to 
support the process (5,6).  
 
As part of its health technology assessment programs, the National Institute of 
Health and Care Excellence (NICE) has often recommended that registers collect 
data for technologies that require more evidence to allow and inform future decision-
making. This has been particularly the case for the Interventional Procedures (IP) 
Programme, which provides guidance for UK health professionals on the safety and 
efficacy of new clinical procedures that involve making a cut through the skin, using 
instruments to enter the body (e.g. an endoscope) or equipment which uses energy 
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sources (e.g. ultrasound) to diagnose or treat patients. These procedures are 
typically not well established, meaning that there is often a paucity of evidence on 
which to make recommendations. Since its establishment in 2003, IP guidance has 
frequently recommended the collection of further data in specific named registers, 
with the intention of enriching the evidence base for the technology in order to inform 
future reviews of the guidance.  
 
The most recent operational manual for the IP programme specifies four standards 
that should be met by any recommended register (see Table 1) (7). Many of the 
registers recommended by NICE were assessed prospectively against the standards 
when guidance was written, but a retrospective audit of the registers has not been 
undertaken to date.  We undertook a survey of registers recommended by the NICE 
IP Programme against these quality standards to a) assess the fitness for purpose of 
recommended registers, and b) assess the quality of registers used in the NICE IP 
program since 2003.  
 
<< Table 1 around here >>  
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Methods 
Questionnaire development 
We constructed a questionnaire based on the four IP quality standards as well as an 
additional question on data publication (see supplementary file 1). This was piloted 
by the IP team as part of its ongoing work to  develop procedure guidance. 
 
Data collection 
All IP guidance recommendations from 2003 to 2016 were reviewed to identify where 
recommendations for data collection through registers had been made and compile a 
list of corresponding registries. We made a maximum of four attempts to contact 
each register 
: an initial email; a reminder email after 4 weeks if no response; a ”firm reminder” 
email sent from the Director of the IP team if no response after 8 weeks; and as a 
final measure emails sent to other contacts within the register asking them to fill in 
the survey if no response after 10 weeks. Registries for registers recommended in 
multiple pieces of guidance were only asked to send one response. 
 
Quality scoring 
Each register was scored independantly by the authors on seven quality standards: 
accessibility, responsiveness,  data publication, data coverage, data validity, 
independent oversight and data protection. Each standard could score zero, one or 
two, giving a maximum of 14 points. The standards and scoring criteria are 
described in Table 2. All registries were scored on accessibility and responsiveness, 
whereas only responding registries were scored on the other five standards. 
Objective evidence of data publication provided by the register was scored by one 
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author. As data coverage, data validity, independent oversight and data protection 
were more subjective, three authors independently scored all survey responses for 
these four standards. A two-way mixed-effect average-measures absolute-
agreement intraclass coefficient  was calculated for each of these standards (8). For 
responding registries, the score for these standards was averaged and added to the 
scores for the other three standards to produce a total score for each register.  
 
 
<< Table 2 around here >>
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RESULTS 
In total, 28 registers have been recommended in IP guidance since 2003 (see 
supplementary file 2). Four of these registers were excluded from the survey (see 
Figure 1 for flow of responses and reasons for exclusion). We obtained full 
responses from 17 of the 24 eligible registries, a response rate of 70.8%. 
 
<< Figure 1 around here >> 
 
For responding registries, the mean total score was 8.5 (standard deviation 2.9,  
range 4 to 14).  Table 3 outlines the number of registries receiving scores of zero, 
one or two for each standard. The intra-class coefficients for the multi-rated 
standards show a high inter-rater reliability for data coverage, but lower (although 
still significant) reliability for the other three standards.  
 
<< Table 3 around here >> 
 
With regard to accessibility, one in four registries did not have any contact details 
available on the internet. In contrast, a third had online data easily accessible for 
secondary analysis. Websites generally did not provide sufficient evidence to allow 
the standards to be assessed without contacting a register representative. As for 
responsiveness, nearly a third of registers responded readily to our request for 
information. Nearly half, however, required follow-up with alternative contacts at the 
register or did not respond at all. The large international registries (for example, the 
International Registry of the Extracorporeal Life Support Organization (ELSO)) were 
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particularly hard to communicate with because it took time to get through to a 
member of staff that could answer questions on quality. 
 
For those registers where their responses allowed quality to be assessed, scores 
broadly tended to be bimodal with either high or low scores across the range of 
quality standards. For example, nearly half of registers had not published any data at 
all compared to over 40% who had (often numerous) peer-reviewed publications. 
Similarly, over two fifths provided ample evidence that they were meeting data 
protection principles, while nearly the same proportion provided no or scant 
evidence. The majority of registers are managed by an independent steering group, 
but over half were not able to confirm that coverage of the data is routinely monitored 
and the data validated. The lowest agreement between raters was seen on the 
standard concerning the clinical relevancy of collected data, with registries rarely 
stating explicitly their process for making modifications to registers. 
10 
 
DISCUSSION 
We undertook a survey of all registers recommended in NICE IP guidance since 
2003. We found the majority of registers inaccessible with relatively little information 
about the standard of data available from the register’s website. Even when 
specifically asked for a response, a number of registries failed to provide any 
information that allowed an objective assessment against pre-defined quality 
standards. Amongst registers from whom information was received, standards 
relating to governance were more often met than those relating to data quality.  
 
This is the first study to our knowledge assessing the quality of registers 
recommended by health technology agencies specifically to support decision 
making. Overall, the quality of recommended registers was disappointing, with a split 
between large registries that scored highly across all standards and smaller 
registries that scored poorly. Registries are often willing to collaborate with regulatory 
and HTA bodies to help with providing relevant “real world” data (9). However, we 
have shown that only a limited number of registers recommended by NICE are 
mature enough to deliver evidence of sufficiently high quality to inform funding 
decisions. In order to ensure HTA bodies are only utilising registers that are fit-for-
purpose, it is important to be able to distinguish between those registries capable of 
providing high-quality observational data and those that require more support to be 
able to do so.  
 
Several authors have reviewed the important characteristics of a register that are 
required for it to deliver high quality data (10),(11). Desirable qualities that have been 
described include strategic national collaborations amongst key stakeholders; an 
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independent steering committee to lead and oversee the register; consensus 
meetings to agree register objectives, minimum dataset and data ownership; 
accessible data processing systems with training for users; data validation with 
specialist clinical support to question and feedback on data submitted. In order to 
evaluate whether a register should be recommended for observational data 
gathering, a standardised quality assessment tool that encompassed these 
characteristics would be useful. While some quality assessment tools already exist, 
including those developed by Parent, AHRQ and Eucomed, none of these have yet 
been become standard (12-14). 
 
This work is useful in piloting methodology that can be developed in line with the 
needs of national initiatives to improve the validity and use of observational data in 
health technology assessment. We performed a comprehensive audit of 
recommended registers, supported by a rigorous process for scoring responses. We 
were constrained by the previously defined quality standards, which would have 
been more meaningful if a set of acceptable evidence were listed against which 
register submissions could be assessed. This was particularly a problem for the 
standard relating to data protection because respondents generally confirmed that all 
legal requirements relating to data protection and information governance are met 
but did not provide evidence.  
 
In conclusion, this audit has shown that not all registers recommended by NICE’s IP 
Programme to date are capable of producing high quality evidence for post-market 
surveillance of new technologies. A standardised quality assessment tool is needed 
to evaluate registers before their recommendation for observational data gathering 
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by decision-making bodies. This learning will be submitted to the EuneHTA Joint 
Action 3 Work Package 5 to inform the development of standards and tools to be 
used by the 78 partner organisations [weblink: http://www.eunethta.eu/news/core-
workpackages].  
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Keypoints 
 This the first study to assess the quality of registers recommended by health 
technology assessment agencies 
 Overall, the quality of recommended registers was disappointing, with a split 
between large registries that scored highly across all standards and smaller 
registries that scored poorly. 
 Only a limited number of registers recommended by NICE are mature enough 
to deliver evidence of sufficiently high quality to inform funding decisions.  
 It is important for health technology assessment agencies to be able to 
distinguish between those registries capable of providing high-quality 
observational data and those that require more support to be able to do so. 
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Figures 
 
Figure 1 Flow of responses 
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Tables 
 
Table 1 Quality standards for registers recommended by the 
Interventional Procedures Programme 
 
Quality standard 
All known procedures (all devices), without exception, are recorded in 
the database 
The data recorded address relevant efficacy and safety outcomes and 
important patient characteristics 
There is independent oversight of the register 
The register complies with the data protection principles laid out in the 
UK Data Protection Act 1998 and any other relevant legislation. 
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Table 2 Quality standards and scoring criteria 
Standard Definition Scoring criteria 
0 1 2 
Accessibility 
Contact details and 
anonymised data for the 
register are available on the 
internet 
No contact details for 
register on internet (i.e. 
no website or webpage) 
Contact details available on 
internet 
Contact details and data available 
for secondary analysis by third 
party 
Responsiveness 
Register responds promptly 
to requests for information 
Chasing through  other 
register contacts 
required before survey 
completed 
Firm reminder required before 
survey completed 
≤ 1 reminder email required before 
survey completed 
Data publication 
Data from the register on 
the interventional procedure 
has been published No or not answered 
Non-peer reviewed 
publication(s) e.g. annual report 
Peer reviewed publication(s) with 
valid reference(s) 
Data coverage 
All known procedures, 
without exception, are 
recorded in the database 
No or Yes without any 
further or incomplete 
information  
Register has access to 
appropriate denominator data 
to assess data coverage 
Validation has been carried out on 
database 
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Data validity 
The data recorded address 
relevant efficacy and safety 
outcomes and important 
patient characteristics 
Yes but no further 
information on how 
standard met 
MHRA/NICE/professional 
representatives were involved 
in dataset design BUT NO 
process in place for making 
modifications to register 
MHRA/NICE/professional 
representatives were involved in 
dataset design AND process in 
place for making modifications to 
register 
Independent 
oversight 
There is independent 
oversight of the register 
No independent 
steering group or a 
commercial conflict of 
interest exists or 
incomplete information 
Independent steering group and 
no commercial conflict of 
interest 
Independent steering group and no 
commercial conflict of interest AND 
on national register OR explicit 
intent to publish 
Data protection 
The register complies with 
the data protection 
principles laid out in the UK 
Data Protection Act 1998 
and any other relevant 
legislation 
0-2 of below criteria met 
(evidence given for 
each) 
3-6 of below criteria met 
(evidence given for each) 
7-8 of below criteria met (evidence 
given for each) 
Data are: (i) used fairly and lawfully; (ii) used for limited, specifically stated purposes; (iii) used in 
a way that is adequate, relevant and not excessive; (iv) accurate; (v) kept for no longer than is 
absolutely necessary; (vi) handled according to people’s data protection rights; (vii) kept safe and 
secure; (viii) not transferred outside the European Economic Area without adequate protection. 
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Table 3 Registries’ score by standard 
Standard  
Number of registries with score (%) Intra-class coefficient  
0 1 2 
All eligible registries, one scorer  
Accessibility 
6/24 
(25.0%) 
10/24 
(41.7%) 
8/24 (33.3%)  
Responsiveness 
9/24 
(37.5%) 
8/24 
(33.3%) 
7/24 (29.2%)  
Only responding registries, one scorer  
Data publication 
8/17 
(47.1%) 
2/17 
(11.8%) 
7/17 (41.2%)  
Only responding registries, three scorers (each score counted uniquely)  
Data coverage 
16/51 
(31.4%) 
13/51 
(25.5%) 
22/51 (43.1%) 0.82  
(95% CI = 0.59 to 0.93, 
F(16,32) = 6.1, 
p<0.001) 
Data validity 
12/51 
(23.5%) 
6/51 
(11.8%) 
33/51 (64.7%) 0.61  
(95% CI = 0.14 to 0.84, 
F(16,32) = 2.6, p=0.011 
Independent 
oversight 
7/51 
(13.7%) 
8/51 
(15.7%) 
36/51 (70.6%) 0.68  
(95% CI = 0.27 to 0.88, 
F(16,32) = 3.1, p=0.004 
Data protection 
22/51 
(43.1%) 
6/51 
(11.8%) 
23/51 (45.1%) 0.65 
(95% CI = 0.23 to 0.86, 
F(16,32) = 3.4, p=0.001 
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